Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA

Charles L. Bennett; Oliver A. Sartor; James O. Armitage; Hagop Kantarjian

doi:10.1016/S1470-2045(16)30653-2

Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA

Charles L. Bennett, Oliver A. Sartor, James O. Armitage, Hagop Kantarjian

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	22-23
Number of pages	2
Journal	The lancet oncology
Volume	18
Issue number	1
DOIs	https://doi.org/10.1016/S1470-2045(16)30653-2
State	Published - Jan 1 2017

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(16)30653-2

Cite this

@article{82aec7a60e924bf7bbe149fef662c060,

title = "Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA",

author = "Bennett, {Charles L.} and Sartor, {Oliver A.} and Armitage, {James O.} and Hagop Kantarjian",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/S1470-2045(16)30653-2",

language = "English (US)",

volume = "18",

pages = "22--23",

journal = "The lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "1",

}

TY - JOUR

T1 - Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA

AU - Bennett, Charles L.

AU - Sartor, Oliver A.

AU - Armitage, James O.

AU - Kantarjian, Hagop

PY - 2017/1/1

Y1 - 2017/1/1

UR - http://www.scopus.com/inward/record.url?scp=85007497510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007497510&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(16)30653-2

DO - 10.1016/S1470-2045(16)30653-2

M3 - Comment/debate

C2 - 28049571

AN - SCOPUS:85007497510

SN - 1470-2045

VL - 18

SP - 22

EP - 23

JO - The lancet oncology

JF - The lancet oncology

IS - 1

ER -

Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this